//]]>

The Science and Business of Drug Discovery (Record no. 17387)

000 -LEADER
fixed length control field 04423nam a22004095i 4500
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140310150235.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 110702s2011 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781441999023
978-1-4419-9902-3
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RM1-950
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 615
Edition number 23
264 #1 -
-- Boston, MA :
-- Springer US,
-- 2011.
912 ## -
-- ZDB-2-SBL
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Zanders, Edward D.
Relator term author.
245 14 - IMMEDIATE SOURCE OF ACQUISITION NOTE
Title The Science and Business of Drug Discovery
Medium [electronic resource] :
Remainder of title Demystifying the Jargon /
Statement of responsibility, etc by Edward D. Zanders.
250 ## - EDITION STATEMENT
Edition statement 1st.
300 ## - PHYSICAL DESCRIPTION
Extent XVII, 397p. 109 illus., 19 illus. in color.
Other physical details online resource.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Introduction -- Introduction to Drugs and Drug Targets -- Background to Chemistry of Small and Large Molecules -- Laying the Foundations: Drug Discovery from Antiquity to the Twenty-First Century -- Drug Discovery Pipeline Overview -- Target Discovery -- Medicinal Chemistry -- Biotherapeutics -- Screening for Hits -- Process Chemistry and Formulation -- Preclinical Development -- Clinical Trials -- Regulatory Affairs and Marketing Approval -- Diagnostics and Personalized Medicine -- Putting it All Together: A Drug Development Case History -- Commercial Aspects of Drug Development -- Challenges and Responses -- Technology Transfer Executives -- Recruitment Executives -- Pharmaceutical Translators and Interpreters.
520 ## - SUMMARY, ETC.
Summary, etc The Science and Business of Drug Discovery is written for those who want to learn about the biopharmaceutical industry and its products whatever their level of technical knowledge. Its aim is to demystify the jargon used in drug development, but in a way that avoids over simplification and the resulting loss of key information. Each of the nineteen chapters is illustrated with figures and tables which clarify some of the more technical points being made. Also included is a drug discovery case history which draws the relevant material together into a single chapter. In recognizing that it is difficult to navigate through the many external resources dealing with drug development, the book has been written to guide the reader towards the most appropriate information sources, including those listed in the two appendices. The following topics are covered: Different types of drugs: from small molecules to stem cells Background to chemistry of small and large molecules Historical background to drug discovery, pharmacology and biotechnology The drug discovery pipeline: from target discovery to marketed medicine Commercial aspects of drug discovery Challenges to the biopharmaceutical industry and its responses Material of specific interest to technology transfer executives, recruiters and pharmaceutical translators   About the Author Dr. Edward D. Zanders has over twenty years’ experience as a scientist and research manager in both a major pharmaceutical company and in smaller biotechnology organizations. He has been responsible for a number of drug discovery programs for diseases such as asthma and rheumatoid arthritis and has been involved in research management at a senior level. He has also published extensively on subjects ranging from biochemistry and immunology to computer-aided drug design; more recently he has written about the application of online networking to drug discovery. In 2004 he founded PharmaGuide Ltd, a training and consultancy company that delivers courses on the drug discovery industry to various professional groups including technology transfer executives, recruiters and technical translators. It is through delivering these courses that he has been able to develop his own way of conveying complex information about drug discovery to non scientists, while at the same time being able to communicate with PhD level scientists at their level of expertise.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
Topical term or geographic name as entry element Toxicology.
Topical term or geographic name as entry element Biomedicine.
Topical term or geographic name as entry element Pharmacology/Toxicology.
Topical term or geographic name as entry element Biomedicine general.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9781441999016
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-1-4419-9902-3
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme
Item type E-Book
Copies
Price effective from Permanent location Date last seen Not for loan Date acquired Source of classification or shelving scheme Koha item type Damaged status Lost status Withdrawn status Current location Full call number
2014-04-04AUM Main Library2014-04-04 2014-04-04 E-Book   AUM Main Library615

Languages: 
English |
العربية